Xencor Q2 net loss $21.7M; Alexion settlement $105M; XmAb819 ESMO presentation

Xencor Inc

Q2 2026 revenue $51.2M (up from $43.6M YoY); net loss $21.7M ($0.29 loss per share) vs $30.8M loss in Q2 2025.
Alexion settlement resolves Ultomiris royalty dispute: $105M total, first $52.5M due Aug 2026, second $52.5M in 2027; no further U.S. royalties.
XmAb819 (ENPP3 x CD3) Phase 1 ccRCC data accepted for oral presentation at ESMO 2026; registration-enabling study planned for 2027.
XmAb541 (CLDN6 x CD3) monotherapy shows ~14% ORR in ovarian, ~28% in germ cell tumors; FDA Fast Track for germ cell; combination with XmAb808 prioritized.
Cash $486.4M at June 30, 2026; expects year-end 2026 cash $420-440M; sufficient to fund operations through 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.